Media
Press Release
29
2025.08
Jiangsu Recbio Technology Co., Ltd. announced 2025 interim results report and latest progress
23
2025.07
Recbio Received The Reply Of The Approval On The Registration Of Shares Issued To The Target Subscriber
30
2025.06
Product Licensing Cooperation Regarding The Recombinant HPV 9-Valent Vaccine REC603 Established Between The Company And India’s Biological E Company
28
2025.03
Jiangsu Recbio Technology Co., Ltd. announced 2024 annual results report and latest progress
Publication New
2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Download
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques